We showed that AD heterogeneity cannot be entirely explained by neuropathological variables (e.g., β-amyloid or tau accumulation), APOE Ɛ4 allele carrier status, or even by differences in age or sex. This evidence concerns the gene MAPT and Alzheimer disease.